Since September 10, 2024, every mammogram facility in the U.S. is required to provide patients with a clear summary of their breast density—bringing awareness of this important factor front and center.¹ 

While breast density significantly influences risk, it’s only one piece of a larger puzzle. To improve early detection and deliver truly personalized care, healthcare providers must regularly monitor breast density and use comprehensive risk assessments like the Tyrer-Cuzick model.² Embracing a comprehensive approach to risk assessment can transform early detection and prevention strategies and save lives. Here are four key considerations to help advance personalized breast cancer prevention. 

#1 The New Standard: Risk Assessment Begins at Age 30 

According to the American Society of Breast Surgeons (ASBrS), all women aged 30 and above should undergo a formal risk assessment to inform their screening care.² Early stratification creates opportunities for: 

• Tailored patient education  

• Informed decisions about supplemental imaging 

• Proactive prevention strategies 

Tools like Tyrer-Cuzick efficiently evaluate both 10-year and lifetime risks by integrating personal and family history, hormonal factors, prior biopsies, and breast density.² 

#2 Why Breast Density Alone Isn’t Enough — But It’s Critical 

Approximately 50% of women over 40 have dense breasts,³ which: 

• Increases breast cancer risk by 1.2x to 2.0x⁴ 

• Reduces mammogram sensitivity due to masking tumors⁴ 

However, dense breasts are not the sole indicator of risk—and not all high-risk women have dense tissue. Regularly updating breast density and incorporating it into risk models is essential because risk and density are fluid, changing over time.³ 

#3 Why Annual Reassessment Matters 

• A 2023 JAMA Oncology study shows slower declines in density over time correlate with increased risk.⁵ 

• Tyrer-Cuzick scores evolve with age, family history updates, weight changes, and new pathology findings.⁶ 

• Without yearly tracking, patients can silently shift into higher risk categories, missing opportunities for earlier intervention. 

#4 How The Ambry CARE Program® Supports This Personalized Approach 

The Ambry CARE Program^® (CARE) simplifies cancer risk assessment by gathering patient personal and family history to accurately calculate Tyrer-Cuzick scores. CARE can also seamlessly embed these TC scores alongside BI-RADS breast density categories (A–D) directly into the electronic health record (EHR). This integration enables clinicians to review and use the most appropriate risk assessment for each patient. This: 

• Provides personalized risk estimates aligned with BI-RADS density categories (A–D). 

• Supports clinicians with actionable insights at the point of care. 

• Moves beyond mere compliance, empowering providers to make precise, evidence-based decisions and supporting informed patient decision-making. 

Combining annual breast density monitoring with a validated, evolving risk model like Tyrer-Cuzick offers the most accurate roadmap for personalized screening and early detection. With tools like CARE enabling real-time, data-driven decision-making, providers can empower patients to take control of their breast health—potentially saving lives through smarter, tailored care. 

1. https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa

2. https://www.breastsurgeons.org/docs/statements/asbrs-ppr-screening-mammography.pdf 

3. https://www.ajronline.org/doi/10.2214/AJR.13.11969 

4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9530665/ 

5. https://pmc.ncbi.nlm.nih.gov/articles/PMC11590558/ 

6. https://pubmed.ncbi.nlm.nih.gov/29621362/